Hong Kong's pharmaceutical sector experienced volatile trading, with a broad pullback today (March 11) following yesterday's market-leading surge. Innovative drug stocks showed significant divergence, with the 100% innovative drug R&D-focused HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) opening higher but closing lower, down 1.81% on reduced volume. Medical stocks also declined overall, with HUAXIA CSI HONG KONG STOCK CONNECT MEDICAL THEME TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND (159137) falling 1.3%.
Examining the performance of the Hong Kong Stock Connect innovative drug sector, most notable movements came from newly added constituents on March 9. Zhonghui Biotech-B surged 19% to a record high, Baoji Pharmaceutical-B rose 14.42% for its third consecutive gain, while BioMap-B retreated 5% after yesterday's sharp rally to new highs. Heavyweight constituents BeiGene and CSPC Pharmaceutical Group fell over 2%, dragging on the sector, with Yingen Biotech-B leading declines with a 6% drop.
Reviewing recent sector trends, the overall trajectory has been upward despite fluctuations. The HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) has rebounded strongly since hitting a record low on March 4, successively reclaiming its 5-day and 10-day moving averages. Although it failed to hold the 20-day moving average today, the trend suggests potential for a breakthrough this week.
The market driver appears to stem from two main factors: First, this year's government work report for the first time designated innovative drugs as an "emerging pillar industry," proposing accelerated development of commercial insurance and promoting high-quality growth in innovative drugs. Second, the total value of Chinese innovative drug outbound licensing deals has already reached $56.8 billion for 2026, equivalent to 41% of the entire 2025 total and exceeding the full-year 2024 level.
What's the outlook for innovative drugs? Analysis indicates that short-term, March-April may bring an earnings disclosure window for innovative drug companies, with several pharmaceutical firms potentially reporting reduced losses or turning profitable. Looking ahead to the full year, major academic conferences including AACR (April), ASCO (May), and ESMO (October) are expected to showcase clinical data updates from domestic innovative drug developers.
Notably, on Monday (March 9), the constituent adjustment for the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) benchmark index took effect, with 13 new additions and no deletions, bringing the total number of constituents to 50. The rebalancing has further strengthened the index's relative advantages:
Updated! Newly eligible innovative drug stocks are included immediately, ahead of most peer indices. Comprehensive! Complete coverage of 50 innovative drug R&D companies, making it the most comprehensive Hong Kong Stock Connect index for innovative drug R&D companies. Enhanced! Companies with market capitalization exceeding 20 billion yuan account for 86% of the index weight, with the top six constituents representing 54.8%, demonstrating significant concentration in industry leaders.
For exposure to the full innovative drug industry chain opportunities, consider HUAXIA CSI HONG KONG STOCK CONNECT MEDICAL THEME TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND (159137), which maintains nearly 40% exposure to CXO companies while also covering popular themes including AI healthcare, brain-computer interfaces, and high-end medical devices. Among its 50 constituents, 41 represent unique listings unavailable in the A-share market.
Data sources: China Securities Index Company, Shanghai, Shenzhen and Hong Kong stock exchanges.
Note: ETF funds do not charge sales service fees. When subscribing for or redeeming fund shares, subscription and redemption agents may charge commissions up to 0.5%, which include relevant fees collected by stock exchanges and registration institutions. Fund fee structures are detailed in respective legal documents.
Risk disclosure: Index constituents shown are for illustrative purposes only. Individual stock descriptions do not constitute investment advice in any form nor represent holding information or trading动向 of any funds managed by the management company. The fund manager assesses the risk rating of HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES and HUAXIA CSI HONG KONG STOCK CONNECT MEDICAL THEME TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND as R4-medium to high risk, suitable for aggressive (C4) and higher risk profile investors. All information appearing herein (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and expressions of any form) serves only as reference, and investors must bear responsibility for any independent investment decisions. Furthermore, any views, analysis, or predictions contained herein do not constitute investment advice of any form to readers, and no liability will be accepted for direct or indirect losses resulting from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of these funds, past performance does not indicate future returns, and fund investment carries risks.
MACD golden cross signals have formed, with several stocks showing good momentum.
Comments